65,437 trials
Tumors
Primary: Maximum Tolerated Dose (MTD) and Maximum Acceptable Dose (MAD) of Dasatinib as Determined by Number of Participants With Dose-Limiting Toxicities (DLTs) Related to…
Parkinson Disease · Parkinson's Disease
Primary: Mean Change From Baseline in the Japanese Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score (in "On" State for the ROP+L-Dopa Group) at Week 52 and…
Schizophrenia
Primary: Change in Total PANSS Score From Baseline to the End of the Double Blind Phase — -19.2; -23.4; -20.5; -17.0 scores on a scale — p=<0.05
Chronic Myelogenous Leukemia · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and Discontinuation — 30; 11; 13; 13 participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Hemoglobin A1C (HbA1c) at Endpoint (Last Observation Carried Forward [LOCF]) — 8.48; 8.47; -1.21; -1.43 percent of glycosylated hemoglobin
Herpes Simplex
Primary: Pharmacokinetics of Single Dose - Tmax — 1.00; 4; 1.02 hours
Psoriasis Vulgaris
Primary: Number of Participants Attaining a 90 Percent Reduction in PASI From Baseline (PASI 90) - ITT — 0; 0; 3; 1 Participants
Chronic Pain
Primary: Pain Intensity Difference (PID15) At 15 Minutes — 0.82; 0.59 Units on a scale — p=<0.0001
Ovarian Neoplasms
Primary: Objective Response (Complete Partial, Stable and Progression) — 1; 8; 10; 20 Participants
Prostate Cancer
Primary: Participants With Markedly Abnormal Change in Vital Signs and Body Weight — 3; 5; 10; 9 participants
Sleep Disorders, Circadian Rhythm · Insomnia · Psychomotor Agitation
Primary: Actigraphic Measurement of Treatment Conditions — 55.02; 9.94 activity
Dental Plaque
Primary: Control Established Plaque in Adults — 2.42; 2.45 Units on a scale — p=<0.05
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Patients With Overall Confirmed Response — 3; 5; 10 participants
Ametropia
Primary: Visual Acuity — 0.01; -0.07 logMAR
Alcoholism
Primary: Number of Subjects Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While on Study — 336; 53 Participants